PARP inhibitors are new cancer drugs that prevent the reparation of damaged tumor cells, which kills these cancer cells. Amazingly, PARP inhibitors barely affect healthy cells in the body, which limits the side effects the patient will experience. Women with ovarian cancer as a result of a BRCA mutation are the most sensitive to PARP inhibitors, but even people who do not have this mutation can benefit from the drug. PARP inhibitors are a treatment for stage II to IV ovarian cancer after the primary treatment or in the case of recurrence. Only patients with high-grade cancers who have received successful chemotherapy treatment are eligible for this drug.